Compare · AIMT vs EARS
AIMT vs EARS
Side-by-side comparison of Aimmune Therapeutics, Inc. (AIMT) and Auris Medical Holding Ltd. (EARS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AIMT and EARS operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- Company
- Aimmune Therapeutics, Inc.
- Auris Medical Holding Ltd.
- Price
- -
- -
- Market cap
- -
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2014
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 0
Latest AIMT
- SEC Form SC 13G/A filed
- Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Aimmune Therapeutics, Inc. In The Northern District Of California
- Nestlé completes acquisition of Aimmune Therapeutics
- Nestlé announces results of tender offer for Aimmune Therapeutics, Inc.
- Nestlé announces results of tender offer for Aimmune Therapeutics, Inc.
- Life-Saving Advancements, Treatments Delivered by Companies Invested in Innovation
- ALERT: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm
- Lifshitz Law Firm, P.C. Announces Investigation of Aimmune Therapeutics, Inc., (NASDAQ:AIMT), Akcea Therapeutics, Inc., (NASDAQ:AKCA), BMC Stock Holdings, Inc., (NASDAQ:BMCH), and Cancer Genetics, Inc., (NASDAQ:CGIX)
- Nestlé commences tender offer for Aimmune Therapeutics, Inc.
- Nestlé commences tender offer for Aimmune Therapeutics, Inc.
Latest EARS
- SEC Form 6-K filed by Auris Medical Holding Ltd.
- SEC Form 6-K filed by Auris Medical Holding Ltd.
- Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio™ Nasal Spray in Prevention and Mitigation of SARS-CoV-2
- Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology
- Auris Medical to Initiate Market Launch of Bentrio™ Nasal Spray in Germany
- Auris Medical Announces Significant Inhibition of Tumor Growth with OligoPhore siRNA Targeting NF-κB in Murine Model of Adult T-Cell Leukemia / Lymphoma
- SEC Form 6-K filed by Auris Medical Holding Ltd.
- SEC Form EFFECT filed by Auris Medical Holding Ltd.
- SEC Form 6-K filed by Auris Medical Holding Ltd.
- Auris Medical Announces Acquisition of RNA Therapeutics Company and Plans for Strategic Repositioning